EP0973866A4 - Adenovirus e1-komplementierende zellinien - Google Patents

Adenovirus e1-komplementierende zellinien

Info

Publication number
EP0973866A4
EP0973866A4 EP98908661A EP98908661A EP0973866A4 EP 0973866 A4 EP0973866 A4 EP 0973866A4 EP 98908661 A EP98908661 A EP 98908661A EP 98908661 A EP98908661 A EP 98908661A EP 0973866 A4 EP0973866 A4 EP 0973866A4
Authority
EP
European Patent Office
Prior art keywords
adenovirus
cell lines
complementing cell
complementing
lines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98908661A
Other languages
English (en)
French (fr)
Other versions
EP0973866A1 (de
Inventor
David Ayares
Ramon Alemany
Wei-Wei Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genstar Therapeutics Corp
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc filed Critical Baxter International Inc
Publication of EP0973866A1 publication Critical patent/EP0973866A1/de
Publication of EP0973866A4 publication Critical patent/EP0973866A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP98908661A 1997-03-04 1998-02-23 Adenovirus e1-komplementierende zellinien Withdrawn EP0973866A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81003997A 1997-03-04 1997-03-04
US810039 1997-03-04
PCT/US1998/003473 WO1998039411A1 (en) 1997-03-04 1998-02-23 Adenovirus e1-complementing cell lines

Publications (2)

Publication Number Publication Date
EP0973866A1 EP0973866A1 (de) 2000-01-26
EP0973866A4 true EP0973866A4 (de) 2000-04-19

Family

ID=25202818

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98908661A Withdrawn EP0973866A4 (de) 1997-03-04 1998-02-23 Adenovirus e1-komplementierende zellinien

Country Status (4)

Country Link
EP (1) EP0973866A4 (de)
JP (1) JP2000509614A (de)
CA (1) CA2283253A1 (de)
WO (1) WO1998039411A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
ATE384785T1 (de) 2001-12-07 2008-02-15 Crucell Holland Bv Herstellung von viren, virusisolaten, und impfstoffen
DE60312039T2 (de) 2002-12-20 2007-11-08 Chromagenics B.V. Mittel und methoden zur produktion eines proteins durch chromatin-öffner, die chromatin zugänglicher für transkriptionsfaktoren machen können
DK1623023T3 (da) 2003-05-09 2009-03-02 Crucell Holland Bv Kulturer af E1-immortaliserede celler og fremgangsmåder til dyrkning deraf til forögelse af produktudbytter derfra
ES2329607T3 (es) 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
JP4811765B2 (ja) * 2004-06-22 2011-11-09 学校法人東海大学 外来遺伝子の誘導発現の制御が可能な発現ベクター
US8039230B2 (en) 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8999667B2 (en) 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
BRPI0517380A (pt) 2004-11-08 2008-10-07 Chromagenics Bv molécula de dna, cassete de expressão, célula hospedeira, e, métodos para gerar uma célula hospedeira que expressa um polipeptìdeo de interesse e para produzir um polipeptìdeo de interesse
SI1809750T1 (sl) 2004-11-08 2012-08-31 Chromagenics Bv Izbira gostiteljskih celic, ki imajo visok nivo izraĹľanja proteina
US20060195935A1 (en) 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
ATE412737T1 (de) 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
PL2350268T3 (pl) 2008-11-03 2015-05-29 Crucell Holland Bv Sposób wytwarzania wektorów adenowirusowych
WO2011045378A1 (en) 2009-10-15 2011-04-21 Crucell Holland B.V. Method for the purification of adenovirus particles
ES2445713T3 (es) 2009-10-15 2014-03-04 Crucell Holland B.V. Proceso para la purificación de adenovirus a partir de cultivos de alta densidad celular
NZ601424A (en) 2010-02-15 2014-07-25 Crucell Holland Bv Method for the production of ad26 adenoviral vectors
SG11201405228VA (en) 2012-03-12 2014-11-27 Crucell Holland Bv Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
EP2827895B1 (de) 2012-03-22 2017-08-09 Janssen Vaccines & Prevention B.V. Impfstoff gegen rsv
AP2015008815A0 (en) 2013-04-25 2015-10-31 Crucell Holland Bv Stabilized soluble prefusion rsv f polypeptides
MY171210A (en) 2013-06-17 2019-10-02 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f polypeptides
MY181175A (en) 2014-11-04 2020-12-21 Janssen Vaccines & Prevention Bv Therapeutic hpv16 vaccines
SI3283634T1 (sl) 2015-04-14 2019-08-30 Janssen Vaccines & Prevention B.V. Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem
JP7189014B2 (ja) 2015-07-07 2022-12-13 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
EP3319634B1 (de) 2015-07-07 2019-08-21 Janssen Vaccines & Prevention B.V. Stabilisierte lösliche präfusionierte rsv-f-polypeptide
EA037295B1 (ru) 2015-08-20 2021-03-05 Янссен Вэксинс Энд Превеншн Б.В. Терапевтические вакцины против hpv18
DK3439672T3 (da) 2016-04-05 2021-02-15 Janssen Vaccines & Prevention Bv Stabiliserede opløselige præfusions-rsv-f-proteiner
JP7233928B2 (ja) 2016-04-05 2023-03-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
CN109922829A (zh) 2016-05-02 2019-06-21 扬森疫苗与预防公司 治疗性hpv疫苗组合
ES2836598T3 (es) 2016-05-30 2021-06-25 Janssen Vaccines & Prevention Bv Proteínas F de RSV prefusión estabilizadas
CN109312362B (zh) 2016-06-20 2022-06-28 扬森疫苗与预防公司 有效和平衡的双向启动子
JP7229151B2 (ja) 2016-07-14 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｐｖワクチン
AU2018217935B2 (en) 2017-02-09 2020-04-30 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
WO2018194438A1 (ko) 2017-04-21 2018-10-25 (주)지뉴인텍 비복제 아데노 바이러스 생산 세포주 및 이의 제조방법
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
WO2019086461A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
AU2018357912B2 (en) 2017-10-31 2023-11-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
JP7438943B2 (ja) 2017-10-31 2024-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー アデノウイルス及びその用途
MX2020004487A (es) 2017-10-31 2020-08-13 Janssen Vaccines & Prevention Bv Adenovirus y usos de estos.
BR112021013507A2 (pt) 2019-01-10 2021-11-16 Janssen Biotech Inc Neoantígenos da próstata e seus usos
AU2020275455A1 (en) 2019-05-15 2021-12-09 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
CN113950333A (zh) 2019-05-15 2022-01-18 扬森疫苗与预防公司 使用基于腺病毒的疫苗预防性治疗呼吸道合胞病毒感染
US20220372515A1 (en) 2019-10-03 2022-11-24 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
BR112022009598A2 (pt) 2019-11-18 2022-08-16 Janssen Biotech Inc Vacinas baseadas em calr e jak2 mutantes e uso dos mesmos
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
WO2021209897A1 (en) 2020-04-13 2021-10-21 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
US20230029453A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022378A1 (fr) * 1995-01-20 1996-07-25 Rhone-Poulenc Rorer S.A. Cellules pour la production d'adenovirus recombinants
WO1996040955A1 (en) * 1995-06-07 1996-12-19 Graham Frank L Adenovirus vectors for gene therapy
CA2177085A1 (en) * 1996-04-26 1997-10-27 National Research Council Of Canada Adenovirus e1-complementing cell lines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2192442C (en) * 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
IL122614A0 (en) 1995-06-15 1998-08-16 Introgene Bv Packaging systems for human recombinant adenovirus to be used in gene therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022378A1 (fr) * 1995-01-20 1996-07-25 Rhone-Poulenc Rorer S.A. Cellules pour la production d'adenovirus recombinants
WO1996040955A1 (en) * 1995-06-07 1996-12-19 Graham Frank L Adenovirus vectors for gene therapy
CA2177085A1 (en) * 1996-04-26 1997-10-27 National Research Council Of Canada Adenovirus e1-complementing cell lines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199821, Derwent World Patents Index; Class B04, AN 1998-231229, XP002130856 *
RITTNER K ET AL.,: "Conditional repression of the E2 transcription unit in E1-E3-deleted adenovirus vectors is correlated with a strong reduction in viral DNA replication and late gene expression in vitro.", JOURNAL OF VIROLOGY, vol. 71, no. 4, April 1997 (1997-04-01), pages 3307-3311, XP002130911 *
See also references of WO9839411A1 *

Also Published As

Publication number Publication date
JP2000509614A (ja) 2000-08-02
CA2283253A1 (en) 1998-09-11
WO1998039411A1 (en) 1998-09-11
EP0973866A1 (de) 2000-01-26

Similar Documents

Publication Publication Date Title
EP0973866A4 (de) Adenovirus e1-komplementierende zellinien
PL337130A1 (en) Alternatively oriented adenovirus
SG63814A1 (en) Thin type cell
TW373796U (en) Keystoke structure
GB2320435B (en) Improvements in Magnotherapy
GB9710773D0 (en) Cytofunnel arrangement
GB9715267D0 (en) Stethescope structure
GB9707849D0 (en) Structure
AU9649198A (en) Enclosed cell
GB2330432B (en) Calculator
GB9717323D0 (en) Cell line
GB2326957B (en) Calculator
GB9801470D0 (en) Cell line
TW347964U (en) Improved structure for pivot
GB9709409D0 (en) Human cell lines
ZA981740B (en) Photovoitaic cell
GB2309863B (en) Cell aligners
TW323625U (en) Can structure
TW507897U (en) Calculator
GB2337401B (en) Cell processor
GB9715495D0 (en) Cell maintenance
TW334678U (en) Dovecote structure
TW446065U (en) Door-in-door structure
HU9700108V0 (en) Structure
PL320543A1 (en) Paddles

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990903

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 5/00 A, 7C 12N 15/63 B, 7C 12N 1/21 B, 7C 12N 15/64 B, 7C 12N 5/10 B, 7C 12N 5/22 B, 7C 12N 15/86 B

A4 Supplementary search report drawn up and despatched

Effective date: 20000303

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20001215

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

TPAD Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOS TIPA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GENSTAR THERAPEUTICS CORPORATION

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ZHANG, WEI-WEI

Inventor name: ALEMANY, RAMON

Inventor name: AYARES, DAVID

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050210